Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 1 (TRAJ1) is a gene segment found within the T cell receptor alpha locus. This locus encodes part of the variable region of the T cell receptor alpha chain through VJ recombination, specifically, the joining (J) region of the gene. TRAJ1 is a non-functional J-segment pseudogene and does not encode a protein or function as a receptor by itself[4]. The T cell receptor as a whole is an essential immune receptor responsible for the recognition of peptide antigens bound to major histocompatibility complex (MHC) molecules, mediating T-cell activation and immune response[1][3][4]. However, TRAJ1 alone is not a therapeutic target, protein, or receptor, and is not relevant for drug targeting or as a biomarker. Key notes: - TRAJ1 is not a protein or receptor, but a genetic segment or pseudogene, and should not be considered a standalone molecular target. - If referencing a druggable target or receptor, refer to the T cell receptor alpha chain (TRAC) or the heterodimeric T cell receptor[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 1 (TRAJ1).